Miyake Nobuyuki, Ando Takafumi, Ishiguro Kazuhiro, Maeda Osamu, Watanabe Osamu, Hirayama Yutaka, Maeda Keiko, Morise Kazuhiro, Matsushita Masanobu, Furukawa Kazuhiro, Funasaka Kohei, Nakamura Masanao, Miyahara Ryoji, Ohmiya Naoki, Goto Hidemi
Nobuyuki Miyake, Takafumi Ando, Kazuhiro Ishiguro, Osamu Maeda, Osamu Watanabe, Yutaka Hirayama, Keiko Maeda, Kazuhiro Morise, Masanobu Matsushita, Kazuhiro Furukawa, Kohei Funasaka, Masanao Nakamura, Ryoji Miyahara, Hidemi Goto, Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya City, Aichi 466-8550, Japan.
World J Gastroenterol. 2015 Jan 7;21(1):254-61. doi: 10.3748/wjg.v21.i1.254.
To evaluate long-term prognosis following cyclosporine treatment by examining the rate of surgery avoidance among cyclosporine responders.
We retrospectively reviewed clinical records for 29 patients diagnosed with severe steroid-refractory ulcerative colitis in our hospital from August 1997 to August 2008 and treated with cyclosporine by continuous intravenous infusion. All patients were treated with intravenous corticosteroids for more than 5 d prior to cyclosporine therapy. Administration was continued for up to 21 d under serum monitoring to maintain cyclosporine levels between 400 and 600 ng/mL. Clinical activity was assessed before and after cyclosporine therapy using the clinical activity index score, with a reduction of ≥ 5 considered to indicate a response. Among responders, we defined cases not requiring surgery for more than 5 years as exhibiting long-term efficacy of cyclosporine. Factors considered to be possibly predictive of long-term efficacy of cyclosporine were sex, age, disease duration, clinical activity index score, C-reactive protein level, hemoglobin level, disease extent, endoscopic findings, and clinical course.
Cyclosporine was not discontinued due to side effects in any patient. Nineteen (65.5%) of 29 patients were considered responders. A statistically significant (P = 0.004) inverse association was observed between an endoscopic finding of "mucosal bleeding" and responsive cases. Fifteen (9 males, 6 females) of these 19 patients were followed for 5 years or more, of whom 9 (60%) exhibited long-term efficacy of cyclosporine. Of the 10 non-responders, 9 (90%) underwent surgery within 6 mo of cyclosporine therapy. None of the following factors had a significant impact on the long-term efficacy of cyclosporine: sex, age, duration of disease, clinical activity index score, C-reactive protein level, hemoglobin level, extent of disease, endoscopic findings, or clinical course. In contrast, a significant association was observed for maintenance therapy with azathioprine after cyclosporine therapy (P = 0.0014).
Maintenance therapy with azathioprine might improve the long-term efficacy of continuously infused cyclosporine for severe steroid-refractory ulcerative colitis patients.
通过检查环孢素反应者中避免手术的比例来评估环孢素治疗后的长期预后。
我们回顾性分析了1997年8月至2008年8月在我院诊断为重度激素难治性溃疡性结肠炎并接受持续静脉输注环孢素治疗的29例患者的临床记录。所有患者在接受环孢素治疗前均接受静脉注射皮质类固醇治疗超过5天。在血清监测下持续给药长达21天,以维持环孢素水平在400至600 ng/mL之间。使用临床活动指数评分评估环孢素治疗前后的临床活动,评分降低≥5被认为表明有反应。在反应者中,我们将5年以上不需要手术的病例定义为环孢素具有长期疗效。被认为可能预测环孢素长期疗效的因素包括性别、年龄、病程、临床活动指数评分、C反应蛋白水平、血红蛋白水平、疾病范围、内镜检查结果和临床病程。
所有患者均未因副作用而停用环孢素。29例患者中有19例(65.5%)被认为有反应。在内镜检查发现“黏膜出血”与有反应病例之间观察到有统计学意义的(P = 0.004)负相关。这19例患者中有15例(9例男性,6例女性)随访了5年或更长时间,其中9例(60%)显示环孢素具有长期疗效。在10例无反应者中,9例(90%)在环孢素治疗后6个月内接受了手术。以下因素均对环孢素的长期疗效无显著影响:性别、年龄、病程、临床活动指数评分、C反应蛋白水平、血红蛋白水平、疾病范围、内镜检查结果或临床病程。相比之下,在环孢素治疗后使用硫唑嘌呤进行维持治疗观察到有显著相关性(P = 0.0014)。
对于重度激素难治性溃疡性结肠炎患者,硫唑嘌呤维持治疗可能会提高持续输注环孢素的长期疗效。